State Street’s Acumen Pharmaceuticals ABOS Stock Holding History

State Street’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.6M	Buy	600,528 +448,800	+296%	+$1.11M	﹤0.01%	3390
2026 Q1	$358K	Buy	151,728 +51,550	+51%	+$131K	﹤0.01%	3734
2025 Q4	$211K	Sell	100,178 -6,500	-6%	-$12.9K	﹤0.01%	3888
2025 Q3	$182K	Hold	106,678	–	–	﹤0.01%	3931
2025 Q2	$124K	Sell	106,678 -414,528	-80%	-$446K	﹤0.01%	3938
2025 Q1	$573K	Sell	521,206 -4,600	-0.9%	-$6.57K	﹤0.01%	3564
2024 Q4	$904K	Buy	525,806 +9,400	+2%	+$22.6K	﹤0.01%	3510
2024 Q3	$1.28M	Buy	516,406 +79,841	+18%	+$217K	﹤0.01%	3439
2024 Q2	$1.06M	Buy	436,565 +354,787	+434%	+$1.13M	﹤0.01%	3466
2024 Q1	$331K	Sell	81,778 -3,300	-4%	-$12.4K	﹤0.01%	3750
2023 Q4	$327K	Buy	85,078 +25,300	+42%	+$75.1K	﹤0.01%	3755
2023 Q3	$248K	Hold	59,778	–	–	﹤0.01%	3869
2023 Q2	$288K	Hold	59,778	–	–	﹤0.01%	3889
2023 Q1	$243K	Hold	59,778	–	–	﹤0.01%	4003
2022 Q4	$323K	Buy	59,778 +12,400	+26%	+$83.3K	﹤0.01%	3923
2022 Q3	$475K	Buy	47,378 +12,900	+37%	+$74K	﹤0.01%	3799
2022 Q2	$162K	Sell	34,478 -150,380	-81%	-$565K	﹤0.01%	4299
2022 Q1	$723K	Buy	184,858 +73,495	+66%	+$400K	﹤0.01%	3908
2021 Q4	$753K	Buy	111,363 +11,588	+12%	+$127K	﹤0.01%	3880
2021 Q3	$1.48M	Buy	+99,775	New	+$1.66M	﹤0.01%	3696

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

State Street's ABOS Position: Q2 2026 in Review

State Street increased its Acumen Pharmaceuticals (ABOS) stake by 296% in Q2 2026, buying an estimated $1.11M and bringing the position to 600,528 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3390.

State Street first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

State Street held 600,528 shares of Acumen Pharmaceuticals worth $1.6M as of Q2 2026.
State Street bought 448,800 Acumen Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
Acumen Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3390 holding.
State Street first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.